We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+25.03%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
Cap. Flow
-$918M
Cap. Flow %
-29.36%
Top 10 Hldgs %
37.92%
Holding
89
New
20
Increased
16
Reduced
29
Closed
16

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$55.4M
2
KOD icon
Kodiak Sciences
KOD
+$42.4M
3
BTSG icon
BrightSpring Health Services
BTSG
+$40.1M
4
CLDX icon
Celldex Therapeutics
CLDX
+$33.4M
5
ILMN icon
Illumina
ILMN
+$31.7M

Top Sells

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$74.8M
2
KRYS icon
Krystal Biotech
KRYS
+$67M
3
CGON icon
CG Oncology
CGON
+$58.5M
4
APGE icon
Apogee Therapeutics
APGE
+$54.4M
5
DHR icon
Danaher
DHR
+$42M

Sector Composition

Rank Sector Weight
1 Healthcare 83.49%
2 Miscellaneous 16.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
26
Vera Therapeutics
VERA
$2.46B
$39.7M 1.27%
784,742
+312,003
+66% +$11.1M
IRTC icon
27
iRhythm Holdings
IRTC
$3.96B
$38.6M 1.23%
217,345
-8,500
-4% -$1.51M
TMDX icon
28
Transmedics
TMDX
$3.07B
$38.4M 1.23%
315,341
-35,907
-10% -$4.51M
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$12.5B
$35.7M 1.14%
601,520
+73,520
+14% +$4M
ILMN icon
30
Illumina
ILMN
$32.6B
$35.4M 1.13%
+269,673
New +$31.7M
KYMR icon
31
Kymera Therapeutics
KYMR
$9.82B
$35.3M 1.13%
454,259
+177,567
+64% +$12M
FULC icon
32
Fulcrum Therapeutics
FULC
$294M
$34.6M 1.11%
3,061,222
+2,841,734
+1,295% +$28.9M
PEN icon
33
Penumbra
PEN
$12.7B
$34.2M 1.1%
110,152
-31,376
-22% -$8.67M
MBX
34
MBX Biosciences
MBX
$3.03B
$32.1M 1.03%
+1,018,600
New +$24.7M
RAPT
35
DELISTED
RAPT Therapeutics
RAPT
$31.5M 1.01%
+929,694
New +$28.9M
CDNA icon
36
CareDx
CDNA
$2.58B
$29.9M 0.96%
1,585,220
-597,561
-27% -$10M
DYN icon
37
Dyne Therapeutics
DYN
$4.68B
$28.9M 0.92%
1,478,329
-1,252,152
-46% -$23.7M
ENGN icon
38
enGene Therapeutics
ENGN
$122M
$28.3M 0.9%
3,131,319
+865,000
+38% +$6.93M
LEGN icon
39
Legend Biotech
LEGN
$3.87B
$28.2M 0.9%
1,298,142
-528,013
-29% -$15.1M
MRVI icon
40
Maravai LifeSciences
MRVI
$1.14B
$27.1M 0.87%
8,353,287
– –
DHR icon
41
Danaher
DHR
$152B
$27.1M 0.87%
118,227
-191,112
-62% -$42M
ARGX icon
42
argenx
ARGX
$64B
$26.1M 0.83%
31,007
-45,084
-59% -$38.6M
NTRA icon
43
Natera
NTRA
$47B
$25.5M 0.82%
+111,500
New +$23.3M
DRUG
44
Bright Minds Biosciences
DRUG
$714M
$25.3M 0.81%
324,358
+20,673
+7% +$1.38M
TERN
45
DELISTED
Terns Pharmaceuticals
TERN
$23.2M 0.74%
+575,321
New +$13.3M
EOLS icon
46
Evolus
EOLS
$587M
$20.6M 0.66%
+3,105,209
New +$21M
BIIB icon
47
Biogen
BIIB
$32.3B
$20.4M 0.65%
+115,700
New +$18.9M
KIDS icon
48
OrthoPediatrics
KIDS
$617M
$19.5M 0.63%
1,100,370
-7,400
-0.7% -$130K
TECX
49
Tectonic Therapeutic
TECX
$696M
$19.3M 0.62%
927,524
+190,657
+26% +$3.54M
VTYX
50
DELISTED
Ventyx Biosciences
VTYX
$17.3M 0.55%
+1,920,255
New +$14.4M
1
2
3 4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2025 Portfolio in Review

As of Q4 2025, Braidwell held 89 positions worth $3.13B, down 7.2% from $3.37B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Braidwell withdrew a net $918M in Q4 2025, closing 16 positions and reducing 29 holdings. Its most notable exit was Globus Medical, an estimated $28.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 73% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Centessa Pharmaceuticals worth $54.7M.

  • Braidwell's largest Q4 2025 buy was Centessa Pharmaceuticals: 2,188,320 shares worth $54.7M.
  • Braidwell added most to Celldex Therapeutics in Q4 2025, an estimated $33.4M increase.
  • Braidwell's biggest Q4 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $74.8M.
  • Braidwell fully exited Globus Medical in Q4 2025, selling an estimated $28.5M.
  • Braidwell's ten largest holdings make up 38% of its $3.13B portfolio in Q4 2025.
  • Braidwell opened 20 new positions and closed 16 in Q4 2025.
  • Braidwell's portfolio value fell 7.2% quarter-over-quarter to $3.13B.

Based on Braidwell's 13F filing for Q4 2025, filed 17 Feb 2026.